World Journal of Dentistry

Register      Login

VOLUME 9 , ISSUE 2 ( March-April, 2018 ) > List of Articles

ORIGINAL RESEARCH

Expression of Heat Shock Protein 27 in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma: An Immunohistochemical Study

Spoorthi B Ravi, Annavajjula Saileela

Keywords : Heat shock protein 27, Leukoplakia, Oral lichen planus, Oral potentially malignant disorders, Oral squamous cell carcinoma, Oral submucous fibrosis.

Citation Information : Ravi SB, Saileela A. Expression of Heat Shock Protein 27 in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma: An Immunohistochemical Study. World J Dent 2018; 9 (2):101-105.

DOI: 10.5005/jp-journals-10015-1516

License: CC BY-SA 4.0

Published Online: 01-10-2016

Copyright Statement:  Copyright © 2018; The Author(s).


Abstract

Aim: The present study aims to estimate as well as compare the amount of immunohistochemical expression of heat shock protein 27 (HSP27) in oral potentially malignant disorders (OPMDs) and oral squamous cell carcinoma (OSCC). Materials and methods: The study group comprised 24 cases of OPMDs, 12 OSCC cases, and 9 normal (controls) oral mucosa specimens. All sections were stained immunohistochemically with HSP27 antibody kit followed by analysis. Results: Increased intensity of staining with statistically significant difference (p = 0.001) was observed in OSCC cases when compared with normal oral mucosa sections. Statistically insignificant results were obtained between OPMDs and normal tissues. Conclusion: Due to significant increase in the staining intensity of OSCC cases when compared with normal sections, HSP27 can be possibly used as a prognostic marker in OSCC cases. Clinical significance: Early diagnosis of malignant transformation through diagnostic markers will markedly improve the overall quality of life. Therefore, early monitoring of the expression of HSP27 in OPMDs will give an insight into their malignant transformation.


PDF Share
  1. Whitley D, Goldberg SP, Jordan WD. Heat shock proteins: a review of the molecular chaperones. J Vasc Surg 1999 Apr;29(4):748-751.
  2. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000 Oct;92(19):1564-1572.
  3. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006 Mar;31(3):164-172.
  4. Tekkesin M, Mutlu S, Aksakalli N, Olgac V. Expression of heat shock proteins 27, 60 and 70 in oral carcinogenesis: an immunohistochemical study. Turk Onkoloji Dergisi 2011;26(3):115-120.
  5. Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair 2012 May;5(1):7.
  6. Lo Muzio L, Leonardi R, Mariggiò MA, Mignogna MD, Rubini C, Vinella A, Pannone G, Giannetti L, Serpico R, Testa NF, et al. HSP 27 as possible prognostic factor in patients with oral squamous cell carcinoma. Histol Histopathol 2004 Jan;19(1):119-128.
  7. Mohtasham N, Babakoohi S, Montaser-Kouhsari L, Memar B, Salehinejad J, Rahpeyma A, Khageh-Ahmady S, Marouzi P, Firooz A, Pazoki-Toroudi H, et al. The expression of heat shock proteins 27 and 105 in squamous cell carcinoma of the tongue and relationship with clinicopathological index. Med Oral Patol Oral Cir Bucal 2011 Sep;16(6):e730-e735.
  8. Deyhimi P, Azmoudeh F. HSP27 and HSP70 expression in squamous cell carcinoma: an immunohistochemical study. Dent Res J (Isfahan) 2012 Mar;9(2):162-166.
  9. Garcia-Garcia V, Bascones-Martínez A, García-Kass AI, Martinelli- Kläy CP, Küffer R, Álvarez-Fernández E, Lombardi T. Analysis of the expression of heat-shock protein 27 in patients with oral lichen planus. Oral Dis 2013 Jan;19(1):65-72.
  10. Bhattacharya S, Chattopadhyay D, Raha S, Mukhopadhyay A. Multidimensional applications of heat shock proteins: a review of the perspectives for environment and health. IJIPLS 2012;2(3):345-355.
  11. Suzuki H, Sugimura H, Hashimoto K. Overexpression of heat shock protein 27 is associated with good prognosis in the patient with oral squamous cell carcinoma. Br J Oral Maxillofac Surg 2007 Mar;45(2):123-129.
  12. Mese H, Sasaki A, Nakayama S, Yoshioka N, Yoshihama Y, Kishimoto K, Matsumura T. Prognostic significance of heat shock protein 27 (HSP27) in patients with oral squamous cell carcinoma. Oncol Rep 2002 Mar-Apr;9(2):341-344.
  13. Lo WY, Tsai MH, Tsai Y, Hua CH, Tsai FJ, Huang SY, Tsai CH, Lai CC. Identification of over-expressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis. Clin Chem Acta 2007 Feb;376(1-2): 101-107.
  14. Leonardi R, Pannone G, Magro G, Kudo Y, Takata T, Lo Muzio L. Differential expression of heat shock protein 27 in normal oral mucosa, oral epithelial dysplasia and squamous cell carcinoma. Oncol Rep 2002 Mar-Apr;9(2):261-266.
  15. Epivatianos A, Poulopoulos AK, Kayavis I, Papanayotou P. Expression of heat shock protein 27 (HSP-27) in oral dysplastic epithelium and squamous cell carcinoma. Balkan Journal of Stomatology 2001;5(2):111-114.
  16. Seoane JM, Varela-Centelles PI, Ramirez JR, Cameselle- Teijeiro J, Romero MA, Aguirre JM. Heat shock proteins (HSP70 and HSP27) as markers of epithelial dysplasia in oral leukoplakia. Am J Dermatopathol 2006 Oct;28(5):417-422.
  17. Lee SS, Tsai CH, Ho YC, Yu CC, Chang YC. Heat shock protein 27 expression in areca quid chewing-associated oral squamous cell carcinomas. Oral Dis 2012 Oct;18(7): 713-719.
  18. Ren YF, Amin A, Malmstrom H. Effects of tooth whitening and orange juice on surface properties of dental enamel. J Dent 2009 Jun;37(6):424-431.
  19. Teughels W, Van Assche N, Sliepen I, Quirynen M. Effect of material characteristics and/or surface topography on biofilm development. Clin Oral Impl Res 2006 Oct;17(S2):68-81.
  20. Quirynen M. The clinical meaning of the surface roughness and the surface free energy of intra-oral hard substrata on the microbiology of the supra-and subgingival plaque: results of in vitro and in vivo experiments. J Dent 1994 Jan;22:S13-S16.
  21. Ahlberg KM, Assavanop P, Tay WM. A comparison of the apical dye penetration patterns shown by methylene blue and India ink in root-filled teeth. Int Endod J 1995 Jan;28(1):30-34.
  22. Camps J, Pashley D. Reliability of the dye penetration studies. J Endod 2003 Sep;29(9):592-594.
  23. Abramovitz L, Lev R, Fuss Z, Metzger Z. The unpredictability of seal after post space preparation: a fluid transport study. J Endod 2001 Apr;27(4):292-295.
  24. Haddix JE, Mattison GD, Shulman CA, Pink FE. Post preparation techniques and their effect on the apical seal. J Prosthet Dent 1990 Nov;64(5):515-519.
  25. Behr M, Rosentritt M, Regnet T, Lang R, Handel G. Marginal adaptation in dentin of a self-adhesive universal resin cement compared with well-tried systems. Dent Mater 2004 Feb;20(2):191-197.
  26. Padmanabhan P, Das J, Kumari RV, Pradeep PR, Kumar A, Agarwal S. Comparative evaluation of apical microleakage in immediate and delayed postspace preparation using four different root canal sealers: an in vitro study. J Conserv Dent 2017 Mar-Apr;20(2):86-90.
  27. Eriksson AR, Albrektsson T. Temperature threshold levels for heat-induced bone tissue injury: a vital-microscopic study in the rabbit. J Prosthet Dent 1983 Jul;50(1):101-107.
  28. Saunders EM, Saunders WP. The heat generated on the external root surface during post space preparation. Int Endod J 1989 Jul;22(4):169-173.
  29. Eriksson JH, Sundström F. Temperature rise during root canal preparation—a possible cause of damage to tooth and periodontal tissue. Swed Dent J 1984;8(5):217-223.
  30. Mozini AC, Vansan LP, Sousa Neto MD, Pietro R. Influence of the length of remaining root canal filling and post space preparation on the coronal leakage of Enterococcus faecalis. Braz J Microbiol 2009 Jan;40(1):174-179.
  31. Oliver CM, Abbott PV. Correlation between clinical success and apical dye penetration. Int Endod J 2001 Dec;34(8): 637-644.
  32. Ioannou L, McClaren BJ, Massie J, Lewis S, Metcalfe SA, Forret L, Delatychi MB. Population-based carrier screening for cystic fibrosis: a systematic review of 23 years of research. Genet Med 2014 Mar;16(3):207-216.
  33. Premera. Noninvasive prenatal screening for fetal aneuploidies and microdeletions using cell-free DNA. Medical Policy No. 4.01.21, 2015. Available at: https://www.premera.com/ medicalpolicies/4.01.21.pdf
  34. Kohane IS, Masys DR, Altman RB. The incidentalome: a threat to genomic medicine. JAMA 2006 Jul;296(2):212-215.
  35. Committee on Ethics, American College of Obstetricians and Gynecologists; Committee on Genetics, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 410: Ethical issues in genetic testing. Obstet Gynecol 2008 Jun; 111(6):1495-502.
  36. American Medical Association. Council on Ethical and Judicial Affairs. Code of medical ethics: current opinions with annotations / American Medical Association, Council on Ethical and Judicial Affairs; annotations prepared by the Southern Illinois University Schools of Medicine and Law, 2006-2007 ed. Chicago, Ill.: AMA Press, 2006. pp 399.
  37. Offit K, Groeger E, Turner S, Wadsworth EA, Weiser MA. The “duty to warn” a patient's family members about hereditary disease risks. JAMA 2004 Sep;292(12):1469-1473.
  38. Fluda KG, Lykens K. Ethical issues in predictive genetic testing: a public health perspective. J Med Ethics 2006 Mar:32(3):143-147.
  39. Committee on Ethics, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 360: Sex selection. Obstet Gynecol 2007 Feb;109(2 Pt 1):475-478.
  40. Braude P. Preimplantation diagnosis for genetic susceptibility. N Engl J Med. 2006 Aug 10;355(6):541-543.
  41. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997 Aug 16;350(9076):485-487.
  42. Benn PA, Chapman AR. Ethical challenges in providing noninvasive prenatal diagnosis. 2010 Apr;22(2):128-134.
  43. Bianchi DW. At-home fetal DNA gender testing: caveat emptor. Obstet Gynecol 2006 Feb;107(2 Pt 1):216-218.
  44. Hall A, Bostanci A, John S. Ethical, legal and social issues arising from cell-free fetal DNA technologies. In: Appendix III to the report: Cell-free fetal nucleic acids for noninvasive prenatal diagnosis. Cambridge: PHG Foundation 2009. Available at: www.phgfoundation.org.
  45. Modell B. Delivering genetic screening to the community. Ann Med 1997 Dec;29(6):591-599.
  46. Peterlin B, Vidmar L, Borry P, et al. Expanded carrier screening tests currently on the commercial market. Eur J Hum Genet 2014; 22 (suppl 1):291.
  47. Kingsmore S. Comprehensive carrier screening and molecular diagnostic testing for recessive childhood diseases. PLoS Curr 2012 May:e4f9877ab8ffa9.
  48. World Health Organization. Identifying regional priorities in the area of human genetics in SEAR: Report of an intercountry consultation, Bangkok, Thailand, 23-25 September 2003. New Delhi: WHO Office for South East Asia Region; 2004. 26p.
  49. World Health Organization. Human Genomics in Global Health. Case Study: India. Geneva: WHO; 2006. Available at: http://www.who.int/genomics/policy/india/en/index7. html#content
  50. World Health Organization. The World Health Report 2005. Make every mother and child count. Geneva, Geneva: WHO; 2005. 219p.
  51. Ghosh, K, Mohanty D. Teaching of medical genetics in the medical colleges of India – way ahead. Ind J Med Genet 2002 Jul-Dec;8(2):43-44.
  52. Ganguly BB, Chakrabarti D. Urge of prenatal diagnosis in modernized civilization. Eur J Hum Genet 2009;17(Suppl. 2): 160.
  53. Dal Pizzol MM, Roggia MF, Kwitko S, Marinho DR, Rymer S. Use of fibrin glue in ocular surgery. Arq Bras Oftalmol 2009 May-Jun;72(3):308-312.
  54. Dintelmann T, Lieb WE, Grehn F. Filtering bleb revision. Techniques and outcome. Ophthalmologe 2002 Dec;99(12): 917-921.
  55. Du TT, Saffra N. Acellular dermal graft as a treatment of recurrent conjunctival wound dehiscence. Arch Ophthalmol 2009 Nov;127(11):1520-1521.
  56. Elmalem VI, Harris GJ. Occurrence and surgical management of a cerebrospinal fluid-filled cystoid space following routine enucleation. Ophthal Plast Reconstr Surg 2012 Sep-Oct;28(5):e117-e118.
  57. Esquenazi S, Rand W, Velazquez G, Grunstein L. Novel therapeutic approach in the management of band keratopathy using amniotic membrane transplantation with fibrin glue. Ophthalmic Surg Lasers Imaging 2008 Sep-Oct;39(5): 418-421.
  58. Freeman PD, Kahook MY, Curtis TH. Glaucoma drainage device implantation in children using fibrin glue. J AAPOS 2010 Apr;14(2):169-171.
  59. Piltz JR, Starita RJ. The use of subconjunctivally administered tissue plasminogen activator after trabeculectomy. Ophthalmic Surg 1994 Jan;25(1):51-53.
  60. Por YM, Tan YL, Mehta JS, Tan DT. Intracameral fibrin tissue sealant as an adjunct in tectonic lamellar keratoplasty for large corneal perforations. Cornea 2009 May;28(4):451-455.
  61. Sakarya Y, Sakarya R, Yildirim A. Sutureless amniotic membrane fixation with fibrin glue in symptomatic bullous keratopathy with poor visual potential. Eur J Ophthalmol 2010 Jan-Feb;20(1):249; author reply 249-250.
  62. Lee GA, Holcombe DJ. Surgical revision of dysfunctional filtration blebs with bleb preservation sliding conjunctival flap and fibrin glue. Eye (Lond) 2010 Jun;24(6):947-953.
  63. Kahook MY, Noecker RJ. Fibrin glue-assisted glaucoma drainage device surgery. Br J Ophthalmol 2006 Dec;90(12):1486-1489.
  64. Valimaki J. Fibrin glue for preventing immediate postoperative hypotony following glaucoma drainage implant surgery. Acta Ophthalmol Scand 2006 Jun;84(3):372-374.
  65. Malhotra C, Jain AK. Human amniotic membrane transplantation: different modalities of its use in ophthalmology. World J Transplant 2014 Jun;4(2):111-121.
  66. Dua HS, Gomes JA, King AJ, Maharajan VS. The amniotic membrane in ophthalmology. Surv Ophthalmol 2004 Jan-Feb;49(1):51-77.
  67. Shimmura S, Shimazaki J, Ohashi Y, Tsubota K. Antiinflammatory effects of amniotic membrane transplantation in ocular surface disorders. Cornea 2001 May;20(4):408-413.
  68. Yazdani S, Mahboobipour H, Pakravan M, Doozandeh A, Ghahari E. Adjunctive mitomycin c or amniotic membrane transplantation for Ahmed glaucoma valve implantation: a randomized clinical trial. J Glaucoma 2016 May;25(5):415-421.
  69. Sheha H, Kheirkhah A, Taha H. Amniotic membrane transplantation in trabeculectomy with mitomycin C for refractory glaucoma. J Glaucoma 2008 Jun-Jul;17(4):303-307.
  70. Khairy HA, Elsawy MF. Trabeculectomy with mitomycin-C versus trabeculectomy with amniotic membrane transplant: a medium-term randomized controlled trial. J Glaucoma 2015 Sep;24(7):556-559.
  71. Rauscher FM, Barton K, Budenz DL, Feuer WJ, Tseng SC. Long-term outcomes of amniotic membrane transplantation for repair of leaking glaucoma filtering blebs. Am J Ophthalmol 2007 Jun;143(6):1052-1054.
  72. Sethi P, Patel RN, Goldhardt R, Ayyala RS. Conjunctival advancement with subconjunctival amniotic membrane draping technique for leaking cystic blebs. J Glaucoma 2016 Feb;25(2):188-192.
  73. Kitagawa K, Yanagisawa S, Watanabe K, Yunoki T, Hayashi A, Okabe M, Nikaido T. A hyperdry amniotic membrane patch using a tissue adhesive for corneal perforations and bleb leaks. Am J Ophthalmol 2009 Sep;148(3):383-389.
  74. Nagai-Kusuhara A, Nakamura M, Fujioka M, Negi A. Longterm results of amniotic membrane transplantation-assisted bleb revision for leaking blebs. Graefes Arch Clin Exp Ophthalmol 2008 Apr;246(4):567-571.
  75. Rai P, Lauande-Pimentel R, Barton K. Amniotic membrane as an adjunct to donor sclera in the repair of exposed glaucoma drainage devices. Am J Ophthalmol 2005 Dec;140(6): 1148-1152.
  76. Ainsworth G, Rotchford A, Dua HS, King AJ. A novel use of amniotic membrane in the management of tube exposure following glaucoma tube shunt surgery. Br J Ophthalmol 2006 Apr;90(4):417-419.
  77. Papadaki TG, Siganos CS, Zacharopoulos IP, Panteleontidis V, Charissis SK. Human amniotic membrane transplantation for tube exposure after glaucoma drainage device implantation. J Glaucoma 2007 Jan;16(1):171-172.
  78. Mulder EJ, Leiblum DM, Visser GH. Fetal breathing movements in late diabetic pregnancy: relationship to fetal heart rate patterns and Braxton Hicks’ contractions. Early Hum Dev 1995 Nov;43(3):225-232.
  79. Schulte FJ, Michaelis R, Nolte R, Albert G, Parl U, Lasson U. Brain and behavioral maturation in newborn infants of diabetic mothers. I. Nerve conduction and EEG patterns. Neuropadiatrie 1969 Jan-Jul;1(1):24-35.
  80. Devoe LD, Youssef AA, Castillo RA, Croom CS. Fetal biophysical activities in third-trimester pregnancies complicated by diabetes mellitus. Am J Obstet Gynecol 1994 Aug;171(2):298-303.
  81. Dierker LJ Jr, Pillay S, Sorokin Y, Rosen MG. The change in fetal activity periods in diabetic and nondiabetic pregnancies. Am J Obstet Gynecol 1982 May;143(2):181-185.
  82. Doherty NN, Hepper PG. Habituation in fetuses of diabetic mothers. Early Hum Dev 2000 Aug;59(2):85-93.
  83. Kainer F, Prechtl HF, Engele H, Einspieler C. Assessment of the quality of general movements in fetuses and infants of women with type-1 diabetes mellitus. Early Hum Dev 1997 Nov;50(1):13-25.
  84. Mulder EJ, O'Brien MJ, Lems YL, Visser GH, Prechtl HF. Body and breathing movements in near-term fetuses and newborn infants of type-1 diabetic women. Early Hum Dev 1990 Nov;24(2):131-152.
  85. Mulder EJ, Visser GH. Growth and motor development in fetuses of women with type-1 diabetes. I. Early growth patterns. Early Hum Dev 1991 May;25(2):91-106.
  86. Mulder EJ, Visser GH. Growth and motor development in fetuses of women with type-1 diabetes. II. Emergence of specific movement patterns. Early Hum Dev 1991 May;25(2):107-115.
  87. Mulder EJ, Visser GH. Impact of early growth delay on subsequent fetal growth and functional development: a study on diabetic pregnancy. Early Hum Dev 1992 Dec;31(2):91-95.
  88. Mulder EJ, Visser GH, Bekedam DJ, Prechtl HF. Emergence of behavioral states in fetuses of type-1 diabetic women. Early Hum Dev 1987 Jul;15(4):231-251.
  89. Mulder EJ, Visser GH, Morssink LP, de Vries JI. Growth and motor development in fetuses of women with type-1 diabetes. III. First trimester quantity of fetal movement patterns. Early Hum Dev 1991 May;25(2):117-133.
  90. Aberg A, Westbom L, Kallen B. Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Hum Dev 2001 Mar;61(2):85-95.
  91. Deregnier RA, Nelson CA, Thomas KM, Wewerka S, Georgieff MK. Neurophysiologic evaluation of auditory recognition memory in healthy newborn infants and infants of diabetic mothers. J Pediatr 2000 Dec;137(6):777-784.
  92. Nelson CA, Wewerka S, Thomas KM, Tribby-Walbridge S, deRegnier R, Georgieff M. Neurocognitive sequelae of infants of diabetic mothers. Behav Neurosci 2000 Oct;114(5):950-956.
  93. Reece EA, Homko CJ. Infant of the diabetic mother. Semin Perinatol 1994 Oct;18(5):459-469.
  94. Reece EA, Homko CJ. Why do diabetic women deliver malformed infants? Clin Obstet Gynecol 2000 Mar;43(1):32-45.
  95. Rizzo T, Metzger BE, Burns WJ, Burns K. Correlations between antepartum maternal metabolism and intelligence of offspring. N Engl J Med 1991 Sep;325(13):911-916.
  96. Rizzo TA, Metzger BE, Dooley SL, Cho NH. Early malnutrition and child neurobehavioral development: insights from the study of children of diabetic mothers. Child Dev 1997 Feb;68(1):26-38.
  97. Schwartz R, Teramo KA. Effects of diabetic pregnancy on the fetus and newborn. Semin Perinatol 2000 Apr;24(2):120-135.
  98. Vaarasmaki MS, Hartikainen A, Anttila M, Pramila S, Koivisto M. Factors predicting peri- and neonatal outcome in diabetic pregnancy. Early Hum Dev 2000 Jul;59(1):61-70.
  99. Robertson SS, Dierker LJ. Fetal cyclic motor activity in diabetic pregnancies: sensitivity to maternal blood glucose. Dev Psychobiol 2003 Jan;42(1):9-16.
  100. Accardo PJ, Blondis TA, Whitman BY. Disorders of attention and activity level in a referral population. Pediatrics 1990 Mar;85(3 Pt 2):426-431.
  101. Ornoy A, Uriel L, Tennenbaum A. Inattention, hyperactivity and speech delay at 2-4 years of age as a predictor for ADDADHD syndrome. Isr J Psychiatry Relat Sci 1993;30(3):155-163.
  102. Smyth TR. Impaired motor skill (clumsiness) in otherwise normal children: a review. Child Care Health Dev 1992 Sep-Oct;18(5):283-300.
  103. Petersen MB, Pedersen SA, Greisen G, Pedersen JF, Mølsted- Pedersen L. Early growth delay in diabetic pregnancy: relation to psychomotor development at age 4. Br Med J (Clin Res Ed) 1988 Feb;296(6622):598-600.
  104. Sells CJ, Robinson NM, Brown Z, Knopp RH. Long-term developmental follow-up of infants of diabetic mothers. J Pediatr 1994 Jul;125(1):S9-S17.
  105. Vladareanu R, Lebit D, Constantinescu S. Ultrasound assessment of fetal neurobehaviour in high risk pregnancies. DSJUOG 2012 Apr-Jun;6(2):132-147.
  106. Talic A, Kurjak A, Ahmed B, Stanojevic M, Predojevic M, Kadic AS, Di Renzo GC. The potential of 4D sonography in the assessment of fetal behavior in high-risk pregnancies. J Matern Fetal Neonatal Med 2011 Jul;24(7):948-954.
  107. Bekedam DJ, Visser GH, de Vries JJ, Prechtl HF. Motor behaviour in the growth retarded fetus. Early Hum Dev 1985 Nov;12(2):155-165.
  108. Cioni G, Prechtl HF. Preterm and early postterm motor behaviour in low-risk premature infants. Early Hum Dev 1990 Sep;23(3):159-191.
  109. Seme-Ciglenecki P. Predictive value of assessment of general movements for neurological development of highrisk preterm infants: comparative study. Croat Med J 2003 Dec;44(6):721-727.
  110. Abo-Yaqoub S, Kurjak A, Mohammed AB, Shadad A, Abdel-Maaboud M. The role of 4-D ultrasonography in prenatal assessment of fetal neurobehaviour and prediction of neurological outcome. J Matern Fetal Neonatal Med 2012 Mar;25(3):231-236.
  111. Athanasiadis AP, Mikos T, Tambakoudis GP, Theodoridis TD, Papastergiou M, Assimakopoulos E, Tarlatzis BC. Neurodevelopmental fetal assessment using KANET scoring system in low and high-risk pregnancies. J Matern Fetal Neonatal Med 2013 Mar;26(4):363-368.
  112. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012 Jan;97(1):28-38.e25
  113. Sirmans SM, Pate KA. Epidemiology, diagnosis and management of polycystic ovary syndrome. Clin Epidemiol 2014; 6:1-13.
  114. Fauser BC, Diedrich K, Bouchard P, Domínguez F, Matzuk M, Franks S, Hamamah S, Simón C, Devroey P, Ezcurra D, et al. Contemporary genetic technologies and female reproduction. Human Reproduction Update 2011 Nov;17(6):829-847.
  115. Balen A, Conway G, Kaltsas G. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995 Aug;10(8):2107-2111.
  116. Azziz R, Sanchez L, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004 Feb;89(2):453-462.
  117. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at longterm follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000 May;52(5):595-600.
  118. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril 2007 Jun;87(6): 1369-1376.
  119. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Givens JHF, Merriman G, editors. The polycystic ovary syndrome. Cambridge, MA: Blackwell Scientific; 1992. p. 377-384.
  120. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 Jan;81(1):19-25.
  121. Azziz R, Carmina E, DeWailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006 Nov;91(11):4237-4245.
  122. Lujan ME, Jarrett BY, Brooks ED, Reines JK, Peppin AK, Muhn N, Haider E, Pierson RA, Chizen DR. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Hum Reprod 2013 May;28(5):1361-1368.
  123. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health 2011 Feb;3:25-35.
  124. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No 108: Polycystic ovary syndrome. Obstet Gynecol 2009 Oct;114(4):936-949.
  125. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008 Mar;89(3): 505-522.
  126. Balen AH. Ovulation induction in the management of anovulatory polycystic ovary syndrome. Mol Cell Endocrinol 2013 Jul;373(1-2):77-82.
  127. Berridge DL, Winter TC. Saline infusion sonohysterography: technique, indications, and imaging findings. J Ultrasound Med 2004 Jan;23(1):97-112.
  128. Allison SJ, Horrow MM, Kim HY, Lev-Toaff AS. Salineinfused sonohysterography: tips for achieving greater success. Radiographics 2011 Nov-Dec;31(7):1991-2004.
  129. O'Neill MJ. Sonohysterography. Radiol Clin North Am 2003 Jul;41(4):781-797.
  130. Bonnamy L, Marret H, Perrotin F, Body G, Berger C, Lansac J. Sonohysterography: a prospective survey of results and complications in 81 patients. Eur J Obstet Gynecol Reprod Biol 2002 Apr;102(1):42-47.
  131. Lindheim SR, Adsuar N, Kushner DM, Pritts EA, Olive DL. Sonohysterography: a valuable tool in evaluating the female pelvis. Obstet Gynecol Surv 2003 Nov;58(11):770-784.
  132. Lindheim SR, Sprague C, Winter TC. Hysterosalpingography and sonohysterography: lessons in technique. AJR Am J Roentgenol 2006 Jan;186(1):24-29.
  133. Jeanty P, Besnard S, Arnold A, Turner C, Crum P. Air-contrast sonohysterography as a first step assessment of tubal patency. J Ultrasound Med 2000 Aug;19(8):519-527.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.